Liminatus Pharma, Inc. (LIMN)

Liminatus Pharma Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2024	FY 2023	FY 2022
Period Ending	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022
Cash & Equivalents	0.06	0.43	5.05
Cash & Short-Term Investments	0.06	0.43	5.05
Cash Growth	-87.10%	-91.40%	-
Other Receivables	-	0.13	0.1
Receivables	3.67	0.95	0.1
Prepaid Expenses	0.16	0.02	0.01
Other Current Assets	1.4	0.84	1.68
Total Current Assets	5.28	2.24	6.84
Property, Plant & Equipment	0	0	0
Other Long-Term Assets	0.13	-	-
Total Assets	5.41	2.24	6.84
Accounts Payable	1.48	0.93	0.51
Accrued Expenses	3.1	0.86	0.44
Short-Term Debt	19.97	16.05	16.5
Other Current Liabilities	0.2	0.2	0.2
Total Current Liabilities	24.75	18.04	17.65
Total Liabilities	24.75	18.04	17.65
Common Stock	4.71	4.71	4.17
Additional Paid-In Capital	4.61	4.61	5.16
Retained Earnings	-28.67	-25.12	-20.14
Shareholders' Equity	-19.34	-15.79	-10.81
Total Liabilities & Equity	5.41	2.24	6.84
Total Debt	19.97	16.05	16.5
Net Cash (Debt)	-19.92	-15.62	-11.45
Net Cash Per Share	-0.18	-0.15	-0.32
Filing Date Shares Outstanding	112.22	112.22	35.56
Total Common Shares Outstanding	112.22	112.22	35.56
Working Capital	-19.47	-15.8	-10.81
Book Value Per Share	-0.17	-0.14	-0.30
Tangible Book Value	-19.34	-15.79	-10.81
Tangible Book Value Per Share	-0.17	-0.14	-0.30

Source: S&P Global Market Intelligence. Standard template. Financial Sources.